Journal Article

Metformin ameliorates osteoporosis by enhancing bone angiogenesis via the YAP1/TAZ-HIF1α axis

Yin, Hao, Gong, Jiang-Shan, Zou, Jing-Tao, Luo, Hao, Long, Cheng, Lin, Zhi-Rou, Wang, Yi-Yi, Wan, Teng-Fei, Chen, Chun-Yuan, Liu, Yi-Wei, Liu, Yu-Qi, Cao, Jia, Zhu, Yong, Ruan, Zhe, Zhu, Guo-Qiang, Zhao, Shu-Shan, Jin, Ling, Luo, Yi, Wang, Zhen-Xing, Li, Zhao-Hui, Hu, Yin, Xie, Hui

2025

Overview

Background Osteoporosis, resulting from an imbalance between osteoclast-mediated bone resorption and osteoblast-mediated bone formation, affects millions globally. Recent studies have identified type H vessels (CD31 hi EMCN hi ) as a specialized subset of bone blood vessels that positively regulate bone formation. This study aims to investigate the effects of metformin on bone mass, strength, and angiogenesis in osteoporotic mice, and to elucidate the underlying molecular mechanisms, particularly focusing on the YAP1/TAZ-HIF1α axis. Methods Osteoporotic mice were administered metformin, and bone mass and strength were measured. In vivo and in vitro angiogenesis assays were performed under hypoxic conditions. Expression levels of YAP1/TAZ and HIF1α were assessed in femoral metaphysis and hypoxia-cultured human microvascular endothelial cells (HMECs). Small interfering RNA was used to interfere with HIF1α or YAP1/TAZ expression in hypoxia-cultured HMECs. Additionally, we employed AAV-mediated overexpression of YAP1/TAZ in vivo to determine whether elevated YAP1/TAZ levels alter metformin’s effects on bone mass and angiogenesis. Results Metformin significantly enhanced bone mass and strength in osteoporotic mice. It also promoted angiogenesis under hypoxia conditions both in vivo and in vitro. Metformin reduced YAP1/TAZ expression while increasing HIF1α expression in both the femoral metaphysis of osteoporotic mice and hypoxia-cultured HMECs. Interference with HIF1α or YAP1/TAZ confirmed that metformin enhances HIF1α and its target genes primarily by inhibiting YAP1/TAZ. Furthermore, overexpression of YAP1/TAZ partially reversed the bone-protective effect of metformin, leading to reduced HIF1α levels and diminished type H vessel formation. Conclusion Our findings suggest that metformin holds promise as a therapeutic agent for osteoporosis by enhancing type H vessel formation through the inhibition of the YAP1/TAZ-HIF1α axis. Graphical abstract

• Publisher: BioMed Central,Springer Nature B.V,BMC
• Subject: Acyltransferases / Adaptor Proteins, Signal Transducing - genetics / Adaptor Proteins, Signal Transducing - metabolism / Angiogenesis / Animals / Biomedical and Life Sciences / Biomedicine / Blood vessels / Bone and Bones - blood supply / Bone and Bones - drug effects / Bone and Bones - metabolism / Design of experiments / Disease Models, Animal / Female / Growth factors / HIF1α / Homeostasis / Humans / Hypoxia / Hypoxia-Inducible Factor 1, alpha Subunit - genetics / Hypoxia-Inducible Factor 1, alpha Subunit - metabolism / Intervention / Kinases / Metformin / Metformin - pharmacology / Metformin - therapeutic use / Mice / Molecular Medicine / Neovascularization, Physiologic - drug effects / Oophorectomy / Osteoporosis / Osteoporosis - drug therapy / Osteoporosis - etiology / Osteoporosis - metabolism / Osteoporosis - pathology / Quantitative analysis / Signal Transduction - drug effects / Tomography / Trans-Activators / Transcription Factors - metabolism / Transcriptional Coactivator with PDZ-Binding Motif Proteins / Type H vessel / Uterus / YAP-Signaling Proteins / YAP1/TAZ